Recent Updates
Recently added Catalysts
ADGM Positive Sentiment

Adagio Medical Reports Third Quarter 2026 Results

Key Takeaway: Adagio Medical Holdings, Inc. reported its financial results for Q3 2026, highlighting its innovative catheter ablation technologies. The Ultra-Low temperature ablation (ULTA) was prominently featured in four presentations at the VT Symposium 2026. This recognition underscores the company's leadership in treating cardiac arrhythmias.

Market Sentiment Analysis

POSITIVE FACTORS

  • Adagio Medical reported strong financial results.
  • ULTA technology was featured in four podium presentations.
  • The company is recognized as a leader in catheter ablation.

Full Press Release Details

LAGUNA HILLS, Calif.--(BUSINESS WIRE)--Adagio Medical Holdings, Inc. (Nasdaq: ADGM) (“Adagio” or “the Company”), a leading innovator in catheter ablation technologies for the treatment of cardiac arrhythmias, today announced financial results for the third quarter ended September 30, 2026. Recent Business Highlights: Ultra-Low temperature ablation (“ULTA”) featured in four podium presentations at the VT Symposium 2026 held October 9-10 in New York, with topics spanning clinical experience, comp

Frequently Asked Questions

What were Adagio Medical's Q3 2026 results?

Adagio Medical reported strong financial results for Q3 2026.

What is ULTA technology?

ULTA stands for Ultra-Low temperature ablation, used for cardiac arrhythmias.

Where was ULTA featured?

ULTA was featured in four presentations at the VT Symposium 2026.

When did the VT Symposium 2026 take place?

The VT Symposium 2026 was held on October 9-10.

Last updated: Nov 16, 2026